Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121641 · ClinicalTrials.gov registry record · Phase 3
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,035
- Enrollment target
NCT00121641 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,035 participants.
The verdict
NCT00121641, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,035 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
Interventions
- DRUG Metformin
- DRUG Saxagliptin
- DRUG Placebo matching Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,035 participants |
| Start Date | 2005-07 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121641
The ClinicalTrials.gov registry entry for NCT00121641 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,035 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00121641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121641 about?
NCT00121641 is a clinical study titled "Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
What is the current status of trial NCT00121641?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2005-07. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00121641?
The interventions under investigation include: Metformin (DRUG), Saxagliptin (DRUG), Placebo matching Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT00121641?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.